Last reviewed · How we verify
NCT05882136: AIPRACUS
Acute Intermittent Porphyria Related Abnormalities in Cardiovascular System
trial in Porphyrias, Hepatic in 180 participants. Completed in 28 February 2024.
28 February 2024
Quick facts
| Lead sponsor | National Institute of Cardiology, Warsaw, Poland |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 180 |
| Start date | 5 April 2019 |
| Primary completion | 28 February 2024 |
| Estimated completion | 28 February 2024 |
| Sites | 2 locations across Poland |
Conditions studied
- Porphyrias, Hepatic — all drugs for Porphyrias, Hepatic →
Sponsor
National Institute of Cardiology, Warsaw, Poland
Who can join
Adults 18 to 65, any sex, with Porphyrias, Hepatic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to assess the changes in the cardiovascular system in patients with acute intermittent porphyria (AIP).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Hypertension and blood pressure profiles in patients with acute intermittent porphyria: a prospective case-control study.
Jaworski K, Wasilewski R, Windyga J, Kowalik I, et al · · 2026 · PMID 42106273 · DOI 10.1016/j.ejim.2026.106920 -
Acute Hepatic Porphyria Should Be Included in the Diagnostic Work-Up of Patients with Resistant Hypertension or Suspected Secondary Hypertension.
de Lima Serrano P, de Mattos Lombardi Badia B, Barile JP, Mendes PM, et al · · 2025 · PMID 39982239 · DOI 10.3390/medsci13010014
Verify or expand the search:
- PubMed search for NCT05882136
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Institute of Cardiology, Warsaw, Poland trials
Trials by the same sponsor.
- NCT07450287 — CardioNETPOL National Registry of Carcinoid Heart Disease · not yet recruiting
- NCT07144189 — AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography · recruiting
- NCT06878729 — Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI · NA · recruiting
- NCT07254572 — Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes · Phase 4 · recruiting
- NCT06275763 — Optimal Medical Treatment of Difficult-to-treat Hypertension · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05882136 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Cardiology, Warsaw, Poland
- Last refreshed: 2 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05882136.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing